SunRock Biopharma is a biopharmaceutical company established with the aim of developing and commercialising therapeutic antibodies directed against different types of tumour pathologies that are difficult to treat. SunRock’s therapeutic approach is oriented toward the development of immuno-oncological antibodies, i.e. antibodies whose action stimulates and supports the patient’s immune system in such a way that it ultimately kills the tumour.
Development of therapeutic, monoclonal, bispecific and bifunctional antibodies for oncology treatment in humans.
SunRock Biopharma develops therapeutic antibodies against Chemokine Receptor 9 (CCR9, C-C chemokine Receptor type 9), for the treatment of acute lymphoblastic leukaemia (T-ALL, T-Cell Acute Lymphoblastic Leukaemia). The family to which this receptor belongs regulates a wide range of biological functions, including leukocyte adhesion and extravasation. The expression of certain chemokine receptors in tumour cells is strongly associated with cancer progression, the development of metastasis and poor prognosis. In 2016, a new pipeline was opened for the development of antibodies directed against the HER3 (Human Epidermal growth factor Receptor 3) target, also called ERBB3 (Receptor tyrosine-protein kinase erbB-3, ERBB3 receptor tyrosine protein kinase). This is a target of recognised therapeutic value.